Stock code: 688065 Stock abbreviation: Kaiser Bio Announcement No.: 2023-008.

Shanghai Kaisai Biotechnology Co., Ltd.

2022 Annual Performance Express Announcement

The board of directors and all directors of the company guarantee that there are no false records or misleading statements in the contents of this announcement.

or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its contents in accordance with the law.

The main financial data for 2022 contained in this announcement are preliminary accounting data and have not been reviewed by an accounting firm.

The specific data is based on Shanghai Kaisai Biotechnology Co., Ltd. (hereinafter referred to as the "Company") in 2022.

The report shall prevail and draw investors' attention to the investment risks.

Key Financial Data and Indicators for 1. 2022

Unit: ten thousand yuan

Changes in the number of subjects in the current period (%)

Before adjustment After adjustment (after adjustment)

Operating income 244,453.75 219,745.67 236,348.26 3.43

Operating profit 71,477.62 73,884.81 72,335.05 -1.19

Total profit 70,253.12 73,994.63 72,444.87 -3.03

Net profit attributable to shareholders of listed companies 55,243.12 60,789.21 59,471.91 -7.11

Run

Deduction attributable to shareholders of listed companies 52,808.25 57,440.83 56,123.53 -5.91

Net profit from non-recurring gains and losses

Basic earnings per share (RMB) 0.95 1.04 1.02 -6.86

Weighted average ROE 5.13% 5.76% 5.60% decrease by 0.47 percentage points

Increase or decrease at the end of the reporting period at the beginning of the reporting period (%)

Before adjustment After adjustment (after adjustment)

Total Assets 1,751,799.15 1,619,832.50 1,618,515.20 8.23

Net capital attributable to shareholders of listed companies 1,094,868.51 1,066,509.58 1,065,192.29 2.79

Production

Share capital (10,000 shares) 58,327.82 41,668.20 41,668.20 39.98

18.28 18.26 2.79 per 18.77 share attributable to owners of the parent company

Net assets (yuan)

Note:

1. The above financial data and indicators are presented in the unaudited consolidated financial statements.

2. The tail difference of the data in the above table is due to rounding of the data.

3. Explanation of reasons for retrospective adjustment or restatement

(1) On December 30, 2021, the Ministry of Finance issued "On the issuance of

Notice No.> (Accounting [2021] No. 35) (hereinafter referred to as "Standard Interpretation No. 15"), which provides for the accounting treatment of external sales of products or by-products produced by an enterprise before its fixed assets are ready for their intended use or in the course of research and development. In accordance with the requirements of the above documents, the Company made corresponding changes to its current accounting policies and retroactive adjustments to comparable data during the reporting period. This change in accounting policy was announced by the Company on August 12, 2022 (Announcement No. 2022-048).

(2) According to the resolution of the 2021 Annual General Meeting of Shareholders, the Company shall, on the basis of the total share capital of 416,681,976 shares registered on the date of registration of the implementation of the equity distribution, deduct 460,930 shares in the special account for repurchase, I .e.

416,221,046 shares as the base, to the full market as of the date of record (July 19, 2022).

The equity division was completed on July 21, 2022 by converting 4 shares for every 10 shares of capital reserve.

therefore, earnings per share for the presentation period are recalculated based on the adjusted number of shares.

Statement of 2. results of operations and financial position

(I) the operating conditions, financial condition and major factors affecting operating results for the reporting period.

1. In 2022, the company realized operating income of 2444.5375 million yuan, up 3.43 year on year. Realize profits

Total profit was 702.5312 million billion yuan, down 3.03 percent from the same period last year, while net profit attributable to owners of the parent company was 552.4312 million billion yuan, down 7.11 percent from the same period last year.

2, the company's total assets at the end of 2022 17,517.9915 million yuan, an increase of 8.23 over the beginning of the period;

The company's equity was $10,948.6851 million, up 2.79 from the beginning of the period.

3, the reporting period, the company's 40000 tons of biological sebacic acid project successfully put into production, in the new crown epidemic repeatedly caused by market changes and various challenges, the company focused on core products to actively respond, revenue increased slightly. Factories around the country are affected by the epidemic to varying degrees, in the application of new biological materials technology development, application landing and other aspects, the company continued to increase investment in research and development.

(II) analysis of the main reasons for the increase or decrease of more than 30 per cent in the above table:

The share capital of the Company at the end of the reporting period increased by 39.98 compared with the beginning of the reporting period, mainly due to the implementation of the annual profit distribution plan of the Company, which increased by 4 shares for every 10 shares of the capital reserve.

3. Risk Alert

The main financial data for 2022 contained in this announcement are preliminary accounting data, which have not been audited by an accounting firm and may differ from the data disclosed in the company's 2022 annual report. The specific data for 2022 is based on the audited data disclosed in the company's 2022 annual report, drawing investors' attention to investment risks.

It is hereby announced.

Shanghai Kaisai Biotechnology Co., Ltd.

Board of Directors

28 February 2023